Vaughn Bryson, Richard Pilnik and Jack Schuler to Join the Elan
Board
Elan Announces Date of 2009 Annual General Meeting and Changes in
Board of Directors
Elan Corporation PLC
Elan Corporation, plc (NYSE: ELN) today announced the date of its 2009
Annual General Meeting (“the AGM”) and changes in the composition of its
Board of Directors.
Annual General Meeting
The 2009 AGM will be held in Dublin on July 16, 2009 at 10:00 a.m.,
British Summer Time (BST). The Notice of the Annual General Meeting will
be sent to shareholders shortly.
Board changes
Elan announced that it will propose the election of three new directors
to the Company’s Board, effective from the close of the 2009 AGM. Mr.
Vaughn D. Bryson and Mr. Jack W. Schuler will join director nominee Mr.
Richard D. Pilnik, whose appointment to the Elan Board was previously
announced on May 12, 2009, as non-executive directors of the Company.
Mr. Kyran McLaughlin, Chairman of the Board, stated, “Vaughn, Richard
and Jack will bring a wealth of management experience and strategic
insights to our Board of Directors, and all three will greatly
strengthen the commercial pharmaceutical experience on the Elan Board.
We look forward to working closely with these new directors for the
benefit of all Elan shareholders.”
In conjunction with the proposed election of the three new directors,
Elan announced the retirement of Floyd Bloom, Ann Gray and Dennis Selkoe
from the Company’s Board of Directors at the forthcoming AGM.
Of the retiring directors, McLaughlin said, “Floyd, Ann and Dennis,
combined, have been key members of the Elan Board for 23 years and
helped guide the Company through some very important times. We thank
them for their many years of service on the Elan Board and are delighted
that Floyd and Dennis will maintain their association with the Company
by continuing to serve on the Science & Technology Committee.”
Mr. Vaughn D. Bryson
Mr. Bryson (70) has over 40 years of experience as an executive, a
director and advisor in the healthcare industry. He spent 32 years with
Eli Lilly and Co. completing his career there as President and Chief
Executive Officer. From April 1994 to December 1996, Mr. Bryson was Vice
Chairman of Vector Securities International, a healthcare focused
investment banking firm. Mr. Bryson was President of Life Science
Advisors, LLC, a healthcare consulting company from 1995 to 2004. He has
served on the board of directors of many public and private companies
including Eli Lilly & Co., Amylin Pharmaceuticals Inc., Quintiles
Transnational and Chiron Corporation. Mr. Bryson received a B.S. in
Pharmacy from the University of North Carolina and completed the Sloan
Program at the Stanford University Graduate School of Business
Administration.
Mr. Richard D. Pilnik
Mr. Pilnik, (52), brings extensive industry experience to Elan, having
served in several leadership positions during his 25-year career at Eli
Lilly and Company. Most recently at Eli Lilly, Mr. Pilnik served as
Group Vice President and Chief Marketing Officer, where he was directly
responsible for commercial strategy, market research and medical
marketing. Prior to that, Mr. Pilnik served as President of Eli Lilly
Europe, Middle East, Africa and the Commonwealth of Independent States
(CIS), a regional organization of former Soviet Republics, where he
oversaw 50 countries and positioned Eli Lilly as the fastest growing
pharmaceutical company in the region. Mr. Pilnik also held several
marketing and sales management positions in the United States, Europe
and Latin America during his tenure at Eli Lilly. Currently, Mr. Pilnik
serves as President of Innovex, the commercial group of Quintiles
Transnational Corp., which is a global pioneer in pharmaceutical
services. Mr. Pilnik holds a B.A. from Duke University and an M.B.A.
from the Kellogg School of Management at Northwestern University.
Mr. Jack W. Schuler
Mr. Schuler (68) has nearly 40 years of experience as an executive, a
director and investor in the healthcare industry. He is currently a
partner in Crabtree Partners, LLC, a private investment firm located in
Lake Forest, Illinois and a director of Medtronic Inc., Quidel Corporate
and Stericycle Inc. He spent 17 years at Abbott Laboratories, where he
rose to the position of President and Chief Operating Officer. Mr.
Schuler left his executive role at Abbott Laboratories to help launch
and grow several healthcare companies, including Ventana Medical Systems
and Stericycle. Mr. Schuler has also served as a member of the board of
directors of ICOS Corporation, Chiron Corporation, Amgen Inc., and
Abbott Laboratories. Mr. Schuler holds a B.S. in Mechanical Engineering
from Tufts University and an M.B.A. from Stanford University Graduate
School of Business.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company
committed to making a difference in the lives of patients and their
families by bringing innovations in science to fill significant unmet
medical needs. Elan shares trade on the New York, London and Dublin
Stock Exchanges. For additional information about the company, please
visit http://www.elan.com.
|
Elan Corporation, plc
|
|
Investors:
|
|
Chris Burns, 800-252-3526
|
|
David Marshall, 353-1-709-4444
|
|
or
|
|
MEDIA:
|
|
Mary Stutts, 650-794-4403
|
|
Niamh Lyons, 353-1-663-3602
|